Vol.19 No.6

Original Article

Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study

Authors

Yoshie Kusunoki1 , Nahoko Tanaka1 , Kaichi Kaneko1 , Tatsuhiro Yamamoto1 , Hirahito End1 , Shinichi Kawai1

  • Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan
Received:

19 June 2009

Accepted:

27 July 2009

Published online:

27 August 2009

Full Text

PDF　(member's only)

Abstract

We conducted a pilot study to investigate whether tacrolimus was effective for treating patients with systemic lupus erythematosus (SLE) without renal involvement. Ten SLE patients with symptoms such as arthritis and erythema, but no active nephritis, were treated with tacrolimus. They included 8 women and 2 men aged from 24 to 62 years [mean ± standard deviation (SD): 42.1 ± 11.3 years]. Tacrolimus was administered at doses of 1-3 mg daily, and efficacy was assessed from the SLE Disease Activity Index (SLEDAI) after 1 year. Two patients ceased treatment due to adverse reactions (after 4 days for chest pain and 7 months for recurrent infections). The other 8 patients completed 1 year of treatment, and significant improvement of disease activity was observed in 6 of them. The mean (±SD) SLEDAI showed a significant decrease after 1 year of tacrolimus therapy, from 6.8 ± 3.1 to 3.4 ± 0.9; p < 0.05 by Student’s paired t test. The mean (±SD) dose of prednisolone also decreased significantly, from 16.8 ± 8.6 to 9.3 ± 4.6 mg/day; p < 0.05. Although a prospective controlled study will be necessary to confirm, tacrolimus might be a treatment option for active SLE without renal involvement.

Key words

Systemic lupus erythematosus - Tacrolimus - Retrospective study - SLEDAI